Alto Neuroscience

R&D

Is this the year for precision psychology? With Amit Etkin

At the Sachs Neuroscience Forum just before the start of JPM 2026 in San Francisco, pharmaphorum spoke with Amit Etkin, CEO of Alto Neuroscience.

R&D

Is precision psychiatry possible?

Anyone who has taken a psychiatric medication knows that the status quo in prescribing is a trial and error approach, with patients often cycling through an array of drugs to find the one t

News

Alto hits a high note with AI-driven depression therapy

Alto Neuroscience has said its therapeutic approach to depression of matching patients to drugs based on brain biomarkers has shown promise in a phase 2a trial.

Is this the year for precision psychology? With Amit Etkin

Is precision psychiatry possible?

Alto hits a high note with AI-driven depression therapy

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Editor's Picks